Early human intervention

Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects

Takuya Yamane, Momoko Imai, Takeshi Bamba, Susumu Uchiyama

Clinical Nutrition ESPEN · 2023 · 56:83–86

Original publication PubMed

Study at a glance

Design: Single-arm prospective intervention study; 12 weeks
Population or model: Healthy adult volunteers
Sample size: 11 participants
Intervention: NMN 250 mg once daily in the morning for 12 weeks
Publication type: Single-arm intervention study
Evidence class: human-study
Research area: Plasma pharmacodynamics and insulin
Trial registration: Not stated in publication source verified for this record.

Study endpoints

Plasma NMN
Plasma NAD+
Postprandial serum insulin
Physiological and laboratory safety measures

Plain-language summary

This small single-arm study gave 250 mg/day NMN to 11 healthy volunteers for 12 weeks and measured plasma NMN and NAD+ monthly.

Plasma NMN and NAD+ increased during supplementation, and postprandial insulin also increased. The size of the NMN and insulin changes varied widely between individuals.

No adverse symptoms were reported, but because there was no placebo group, the study cannot establish comparative clinical benefit or determine whether other changes were caused by NMN.

Key findings

Plasma NMN increased during oral supplementation.
Plasma NAD+ increased during supplementation.
Postprandial serum insulin increased, with substantial person-to-person variability.
No adverse symptoms were observed in the 11 participants.
The study had no control group.

Limitations

Only 11 participants.
No placebo or untreated control group.
The main endpoints were biochemical rather than clinical outcomes.
Wide interindividual variability in NMN and insulin responses.
The study does not establish long-term benefit or safety.

Funding and transparency

Funding

Not stated in publication source verified for this record.

Competing interests

Not stated in publication source verified for this record.

HealthspanX observation

The increase in postprandial insulin is a biologically relevant finding and should be presented alongside the NAD pharmacodynamic result rather than omitted.

Interpretive weight

Limited

Small uncontrolled 12-week study that demonstrates plasma pharmacodynamic changes but cannot establish comparative efficacy.

This record summarizes a publication; it is not medical advice or a claim that a HealthspanX product reproduces the study's results. Report a correction.

Explore HealthspanX

Science

Your wellbeing